The expansion of traditional Chinese medicine formula granules is imminent, and the top pharmaceutical companies are speeding up their deployment

[Pharmaceutical Network Market Analysis] Traditional Chinese medicine formula granules are granules made of single-flavored Chinese medicine pieces after decoction, concentration, drying, and supplemented by auxiliary materia.
Patients do not need to decoct and take them directly, which is convenient and fa.
Data show that since the pilot program of traditional Chinese medicine formula granules, the industry has maintained rapid grow.
From 2016 to 2020, its main business income has increased from 228 million yuan to about 25 billion yuan, with an average annual growth rate of 4
With the acceleration of unified standard work and inter-provincial joint procurement, policy dividends are continuously released, and the market of traditional Chinese medicine formula granules is considered to be expandi.
Many institutions predict that by 2030, the market size of traditional Chinese medicine formula granules may reach 100 billion yu.
According to the industry, as relevant enterprises increase their investment in the traditional Chinese medicine formula granule industry and provide policy support, the traditional Chinese medicine formula granule industry will move towards a standardized and healthy development, and enterprises in the traditional Chinese medicine formula granule industry will usher in good news in a short period of ti.
Among them, according to the 2021 performance report data released by a number of pharmaceutical companies, the revenue of traditional Chinese medicine formula granules business has achieved year-on-year grow.
For example, Hongri Pharmaceutical will achieve a year-on-year increase of 46% year-on-year in the revenue of traditional Chinese medicine formula granules and decoction pieces in 2021, reaching 235 billion yuan; Shenwei Pharmaceutical's sales revenue of traditional Chinese medicine formula granules in 2021 will increase by 25% year-on-year to 693 million yu.
In 2021, China Resources Sanjiu’s prescription drug business achieved a year-on-year increase of 76% in operating income to 350 billion yuan, of which the specialist and traditional Chinese medicine formula granule business achieved rapid grow.
In addition, China Resources Sanjiu said in an investigation on July 19 and 20 that formula granules have maintained rapid growth in the Sanjiu system in the past few yea.
It is reported that on November 1, 2021, the traditional Chinese medicine formula granules completed the pilot work of more than 20 years, included in the management of traditional Chinese medicine pieces, and officially implemented the filing syst.
Since then, many leading pharmaceutical companies are accelerating the deployment of the traditional Chinese medicine formula granule indust.
According to relevant statistics, in the past year, more than 30 listed pharmaceutical companies, including Jilin Aodong, Essence Pharmaceuticals, Zuoli Pharmaceuticals, e.
, have clearly laid out traditional Chinese medicine formula granul.
For example, Jilin Aodong’s announcement on the evening of May 19 showed that Yanbian Pharmaceutical, a subsidiary of the company, recently received 8 “Recording Certificates for the Listing of Chinese Medicine Formula Granule.
.
According to the industry, traditional Chinese medicine formula granules belong to an industry with a good private consumption base and favorable polici.
Overall, the market is very optimist.
In recent years, the traditional Chinese medicine formula granule industry has also received favorable policies "red envelope.
Analysts pointed out that the two-wheel drive of "policy + market", the traditional Chinese medicine formula granule industry is expected to usher in a rise in both quantity and quality, which will benefit leading and upstream enterprises in the industry cha.
Chinese herbal decoction pieces (including Chinese herbal formula granules) are exempt from "zero marku.
With the expansion of hospital and medical insurance coverage, the industry is expected to continue to grow at a high ra.
In recent years, under the background of the country's strong support for the development of the traditional Chinese medicine industry, the traditional Chinese medicine industry has ushered in a period of opportunity, and as the traditional Chinese medicine formula granules and Chinese medicine decoction pieces have been included in the national and even local medical insurance reimbursement scope, the traditional Chinese medicine market will usher in more positives Influence, the industrial market may further expa.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.